The 50 biggest pharmaceutical companies in Romania last year generated turnover worth 1.79bn euros, namely 1.5% in GDP, according to ZF calculations based on data from Cegedim market research firm. They saw sales go down by around 2% (in euros) against 2008 results, but generated almost 94% of the entire market together. The top position in the ranking is held by Sanofi-Aventis, which came to be the leader after acquiring Zentiva, with turnover worth above 190m euros, while the company ranking 50th, Mundipharma, derives around 3m euros. The best results were registered by US Amgen, with a 52% advance, while Standa and Labormed coped with the steepest declines. Dan Vasile, general manager of Biofarm, believes such increases were generated by a series of conditions, which have not been specific to the Romanian market so far. Overall, 21 pharmaceutical companies posted growth, three saw their figures stagnate and the rest of 26 companies posted declines. The top 20 companies account for almost 80% in sales, compared with 70% a year ago, but the industry is witnessing a strong concentration trend.
The 50 biggest pharmaceutical companies in Romania last year generated turnover worth 1.79bn euros, namely 1.5% in GDP, according to ZF calculations based on data from Cegedim market research firm. They saw sales go down by around 2% (in euros) against 2008 results, but generated almost 94% of the entire market together. The top position in the ranking is held by Sanofi-Aventis, which came to be the leader after acquiring Zentiva, with turnover worth above 190m euros, while the company ranking 50th, Mundipharma, derives around 3m euros. The best results were registered by US Amgen, with a 52% advance, while Standa and Labormed coped with the steepest declines. Dan Vasile, general manager of Biofarm, believes such increases were generated by a series of conditions, whi
